During the past decade, Rigshospitalet; Hæmatologisk Klinik conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rigshospitalet; Hæmatologisk Klinik" #1 collaborator was "Biogen" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Rigshospitalet; Hæmatologisk Klinik" are "Diffuse Large B-cell Lymphoma" (2 trials), "Cancer" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Diffuse Large B-Cell Lymphoma" (1 trials) and "Glioblastoma" (1 trials). Many other conditions were trialed in "Rigshospitalet; Hæmatologisk Klinik" in a lesser frequency.

Most popular intervention types in "Rigshospitalet; Hæmatologisk Klinik" are "Drug" (8 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "Rituximab" (3 trials), "Atezolizumab" (2 trials), "Doxorubicin" (2 trials) and "Obinutuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rigshospitalet; Hæmatologisk Klinik" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Rigshospitalet; Hæmatologisk Klinik". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Rigshospitalet; Hæmatologisk Klinik, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rigshospitalet; Hæmatologisk Klinik, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".